Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution [PDF]
Pharmaceutics, 2022 Niclosamide is an FDA-approved anthelmintic that is being studied in clinical trials as a chemotherapeutic and broad-spectrum antiviral. Additionally, several other applications are currently in the preclinical stage.
Miguel O. Jara +7 more
doaj +4 more sources
Biopharmaceutical Study on Nobiletin-Loaded Amorphous Solid Dispersion with Improved Hypouricemic Effect [PDF]
Molecules, 2021 The present study aimed to develop an amorphous solid dispersion of nobiletin (ASD/NOB) using hydroxypropyl cellulose-SSL (HPC-SSL) to improve the pharmacokinetic properties and hypouricemic effect of NOB. ASD/NOB was prepared by the freeze-drying method
Takuya Nihei +3 more
doaj +4 more sources
Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution [PDF]
Biomedicines, 2023 This study compares the effects of pre-processing multiple polymers together to form a single-phase polymer alloy prior to amorphous solid dispersion formulation.
Stephen A. Thompson +4 more
doaj +2 more sources
Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies [PDF]
Acta Pharmaceutica Sinica B, 2021 Amorphous solid dispersions (ASDs) are popular for enhancing the solubility and bioavailability of poorly water-soluble drugs. Various approaches have been employed to produce ASDs and novel techniques are emerging.
Sonal V. Bhujbal +8 more
doaj +2 more sources
Co-Amorphous Solid Dispersion System for Improvement in Dissolution Profile of N-(((1r,4r)-4-((6-fluorobenzo[d]oxazol-2-yl)amino)cyclohexyl)methyl)-2-methylpropane-2-sulfonamide as a Neuropeptide Y5 Receptor Antagonist [PDF]
PharmaceuticsBackground/Objectives: Brick dust molecules exhibit high melting points and ultralow solubility. Overcoming this solubility issue is challenging. Previously, we formulated a co-amorphous system for a neuropeptide Y5 receptor antagonist (NP) as a brick ...
Hironori Tanaka, Hiroshi Ueda
doaj +2 more sources
Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs [PDF]
Pharmaceutics, 2021 Calquence® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated ...
Deanna M. Mudie +8 more
doaj +2 more sources
Enhancing hepatoprotective action: oxyberberine amorphous solid dispersion system targeting TLR4 [PDF]
Scientific ReportsOxyberberine (OBB) is a significant natural compound, with excellent hepatoprotective properties. However, the poor water solubility of OBB hinders its release and absorption thus resulting in low bioavailability.
Tingting Chen +7 more
doaj +2 more sources
Amorphous Solid Dispersion as Drug Delivery Vehicles in Cancer [PDF]
Polymers, 2023 Diah Lia Aulifa +2 more
exaly +2 more sources
Pharmaceutics, 2018 In order to improve the aqueous solubility and dissolution of Tacrolimus (TAC), amorphous solid dispersions of TAC were prepared by hot melt extrusion with three hydrophilic polymers, Polyvinylpyrrolidone vinyl acetate (PVP VA64), Soluplus® and ...
Poovizhi Ponnammal +4 more
doaj +3 more sources
Optimization of amorphous solid dispersion techniques to enhance solubility of febuxostat [PDF]
Folia Medica, 2021 Febuxostat is a selective inhibitor of xanthine oxidase and belongs to BCS class II drugs having low solubility and high permeability. Solubility is the most important parameter which directly affects dissolution, absorption and bioavailability of the ...
Vaishali P. Patel +2 more
doaj +3 more sources